Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2019 3
2020 8
2021 15
2022 12
2023 21
2024 6

Text availability

Article attribute

Article type

Publication date

Search Results

48 results

Results by year

Filters applied: . Clear all
Page 1
Nemolizumab plus topical agents in patients with atopic dermatitis (AD) and moderate-to-severe pruritus provide improvement in pruritus and signs of AD for up to 68 weeks: results from two phase III, long-term studies.
Kabashima K, Matsumura T, Komazaki H, Kawashima M; Nemolizumab JP01 andJP02 Study Group. Kabashima K, et al. Br J Dermatol. 2022 Apr;186(4):642-651. doi: 10.1111/bjd.20873. Epub 2021 Dec 21. Br J Dermatol. 2022. PMID: 34726262 Free PMC article. Clinical Trial.
Survival rates of systemic interventions for psoriasis in the Western Japan Psoriasis Registry: A multicenter retrospective study.
Yanase T, Tsuruta N, Yamaguchi K, Ohata C, Ohyama B, Katayama E, Sugita K, Kuwashiro M, Hashimoto A, Yonekura K, Higashi Y, Murota H, Koike Y, Matsuzaka Y, Kikuchi S, Hatano Y, Saito K, Takahashi K, Miyagi T, Kaneko S, Ota M, Harada K, Morizane S, Ikeda K, Furue M, Nakahara T, Okazaki F, Sasaki N, Okada E, Yoshida Y, Ito K, Imafuku S. Yanase T, et al. J Dermatol. 2023 Jun;50(6):753-765. doi: 10.1111/1346-8138.16737. Epub 2023 Feb 14. J Dermatol. 2023. PMID: 36786158
48 results